Publication Details
Issue: Vol 19, No (2025)
Pages: 26-27

Abstract

SGLT2 inhibitors (dapagliflozin) belong to a group of modern drugs with proven efficacy in chronic heart failure and chronic kidney disease. However, treatment response varies significantly among patients. The pharmacogenetic approach enables prediction of treatment efficacy based on genotypes and development of personalized treatment strategies.

Keywords
cardiorenal syndrome SGLT2 inhibitor dapagliflozin pharmacogenetics personalized medicine